ReviewInternational journal of hematologic oncology2018
Current trends in the management of Richter's syndrome.
Review in International journal of hematologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.Blood · 2021Trial
- Efficacy and safety of BTK inhibitors in Richter's transformation: a systematic review of clinical evidence.Frontiers in oncology · 2025Review
- An extranodal Richter's syndrome presenting with cardiac diffuse large B-cell lymphoma: a case report.BMC cardiovascular disorders · 2023Article
- Lung Adenocarcinoma with Chronic Lymphocytic Leukemia Mimicking Bone Metastasis.Internal medicine (Tokyo, Japan) · 2023Article
- Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop.American journal of clinical pathology · 2023Article
- A Hepatitis B Virus Reactivation Case Potentially Triggered by the Onset of Diffuse Large B Cell Lymphoma.Internal medicine (Tokyo, Japan) · 2023Article
- In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities.Blood cancer discovery · 2023Article
- Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature.Clinical case reports · 2022Article
- Richter Transformation: Clinical Manifestations, Evaluation, and Management.Journal of the advanced practitioner in oncology · 2022Article
- Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation.Cancer genetics · 2022Article
- Review
- Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.Haematologica · 2021Article
- Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.Cancers · 2021Review
- Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR).Journal of clinical and experimental hematopathology : JCEH · 2021Article
- Article
- Article
- AKT: a key to RT?Blood · 2021Article
- Chronic Lymphocytic Leukemia.Cold Spring Harbor perspectives in medicine · 2021Review
- Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.Blood advances · 2021Article
- The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.Journal of experimental pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Richter's syndrome (RS) is a life-threatening complication of chronic lymphocytic leukemia (CLL). While previous research has increased our knowledge on the distinct evolutionary patterns of RS and provided a deeper understanding of the risk factors and molecular events predisposing to transformation, there remain few targetable aberrations and treatment is largely ineffective. The ability to obtain deeper remissions, without selecting for deletion 17p, by using novel B-cell receptor (BCR) antagonists and bcl2 inhibition might lead to a decrease in the incidence of RS, but these agents have done little to significantly change outcomes when incorporated into treatment regimens for RS. In this review we highlight the current landscape of molecular lesions specific to RS, review the data on historical treatment options, and look to the horizon for potential opportunities in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.